For four years, former Novartis CEO Joe Jimenez and his research righthand, Mark Fishman, have been running Aditum Bio. The Oakland, CA-based venture firm in-licenses drugs on the cusp of human trials and puts them into individual companies that can be sold off if the early-stage results are good.
They’re…
Click here to view original post
